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Prevalence of Cervical, Oral, and Anal Human Papillomavirus Infection in Women Living with HIV 
in Denmark – the SHADE Cohort study 
Running title:  
HPV at three anatomical sites in women living with HIV. 
 
Kristina Thorsteinsson1, Merete Storgaard2, Terese L. Katzenstein3,4, Steen Ladelund5, Frederikke F 
Rönsholt3, Isik Somuncu Johansen6, Gitte Pedersen7, Anne Gaardsting1, Lars Nørregård Nielsen8, 
Jesper Bonde9, and Anne-Mette Lebech3. 
 
1Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre; 2Department of 
Infectious Diseases, Skejby, Aarhus University Hospital; 3Department of Infectious Diseases, 
Copenhagen University Hospital, Rigshospitalet; 4Institute of Clinical Medicine, University of 
Copenhagen; 5Clinical Research Center, Hvidovre, Copenhagen University Hospital;  6Department of 
Infectious Diseases, Odense University Hospital; 7Department of Infectious Diseases, Aalborg 
University Hospital; 8Department of Infectious Diseases, Nordsjællands Hospital, Copenhagen 
University Hospital; 9Department of Pathology, Copenhagen University Hospital, Hvidovre, 
Denmark. 
 
Tables and Figures: 4 + 1 
Supplementary files: 2 
Word count (article): 2,497 
References: 54 
Word count (abstract): 246 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
2 
 
Highlights 
 Cervical and anal HPV infection is highly prevalent in women living with HIV 
 Anal HPV infection is associated with cervical HPV infection 
 Non-16/18 hrHPV genotypes were predominant at all anatomical sites  
 Half of hrHPV infections could have been prevented by the 9-valent HPV vaccine 
 
Description of paper: 
Study on the Prevalence and Distribution of HPV at three Anatomical Sites in Women Living  
with HIV  
 
Abstract  
Background: 
Women living with HIV (WLWH) have elevated risk of human papillomavirus (HPV) related cancers. 
Objectives: 
To assess prevalence, distribution and concordance of cervical, oral, and anal HPV infection, and 
predictors of oral and anal HPV in WLWH in Denmark. 
Study design: 
WLWH followed in the Study on HIV, cervical Abnormalities and infections in women in Denmark 
(SHADE) were enrolled and examined for cervical, oral, and anal HPV infection. Logistic regression 
models were used to identify predictors of anal and oral HPV. 
Results:  
A total of 214 of 334 WLWH had sufficient DNA for analysis at all three anatomical sites and were 
included in analyses. Cervical, oral, and anal high-risk (hr) HPV prevalence were 28.0%, 3.7% and 
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39.3%. Most frequent i) cervical, ii) oral and iii) anal hrHPV genotypes were i) hrHPV58 (8.4%), 52 
(5.1%), 16 (5.1%) and 51 (5.1%); ii) 52 (1.4%) and iii) 51 (9.3%), 58 (8.9%), 16 (7.0%) and 18 (7.0%). 
Among present cervical, oral, and anal hrHPV genotypes, 6.7%, 12.5% and 17.9% were targeted by 
the 2-or 4-valent HPV vaccines, whereas 50.0%, 50.0% and 42.9% of hrHPV genotypes were 
covered by the 9-valent HPV vaccine. Anal HPV infection was predicted by cervical HPV infection 
(adjusted OR 4.47 (95%CI 2.25-8.89)). 
Conclusion:  
Cervical and anal HPV infection were highly prevalent in WLWH. Non-16/18 hrHPV genotypes 
were predominant at all anatomical sites. Almost half of all hrHPV infections at the three 
anatomical sites could have been prevented by childhood/adolescent vaccination with the 9-
valent HPV vaccine.  
 
List of abbreviations used  
AC  Anal cancer 
AIN  Anal intraepithelial neoplasia 
ART  Antiretroviral therapy 
CC  Cervical cancer 
CI  Confidence interval  
CIN  Cervical intraepithelial neoplasia  
CRS  Civil Registration System 
DF  Degrees of freedom  
DHCS  Danish HIV Cohort Study 
EACS  European AIDS Clinical Society 
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HR  High-risk 
HPV  Human papillomavirus 
MSM  Men who have sex with men 
LR  Low-risk 
OPC  Oropharyngeal cancer  
OR  Odds ratio  
PIN  Personal identification number  
PLWH  People living with HIV 
SHADE Study on HIV, cervical Abnormalities and infections in women in 
Denmark 
WLWH  Women living with HIV 
 
Key words:  
Women living with HIV; human papillomavirus; cervical cancer, anal cancer; oral cancer; genotype 
distribution; HPV vaccine, concordance, HPV prevalence. 
 
Background 
Five percent of the world’s cancer burden is attributable to human papillomavirus (HPV) infection 
[1], and people living with HIV (PLWH) have elevated risk of HPV related cancers at different 
anatomical sites, compared to their HIV-negative peers [2-4]. Especially increased risk of HPV-
related cervical cancer (CC) [2,5-9], oropharyngeal cancer (OPC) [5,10,11], and anal cancer (AC) 
[5,12] has been reported [2,5-9]. Whereas HPV is the causal agent of CC, the prevalence of HPV in 
OPCs is 25-46% [13,14] and 58-100% in ACs [15,16].  
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The exact mechanisms behind the interactions between HIV and HPV at a cellular level are not 
clearly understood; HIV may facilitate access and entry of HPV to basal epithelial cells by 
disrupting the epithelial tight junctions [17] and HIV-mediated immunodeficiency can increase 
HPV acquisition, reactivation and persistence. We previously reported that prevalent cervical high-
risk (hr) HPV infection in WLWH participating in the Study on HIV, cervical Abnormalities and 
infections in women in Denmark (SHADE) was predicted by factors associated with 
immunosuppression; CD4 <350 cells/μL, prior AIDS and short duration of combined antiretroviral 
treatment (ART) [18].    
HPV vaccine initiatives targeting PLWH require knowledge on concordant HPV genotype 
distribution at all anatomical sites to estimate multisite vaccine efficacy. While several studies on 
women living with HIV (WLWH) report cervical, oral, or anal HPV genotype distribution [19-25], 
only few, small studies have addressed concurrent cervical, oral, and anal HPV prevalence [26-28].  
 
Objectives 
The aim of the present study was to assess the prevalence, distribution and concordance of 
cervical, oral, and anal HPV in WLWH in Denmark. Furthermore, we aimed at identifying predictors 
of oral and anal HPV. 
 
Study design: 
Setting  
Denmark has a population of 5.7 million [29] and an estimated HIV prevalence among adults of 
0.1% [30]. Medical care, including ART, is tax-paid and provided free-of-charge to all PLWH [22]. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
6 
 
Treatment of HIV is restricted to eight specialized medical centres. Six of these centres 
participated in the SHADE [22]. PLWH are visiting outpatient clinics at intended intervals of 3-6 
months [31]. During the study period, HIV guidelines recommended cervical cytology twice the 
first year after HIV diagnosis and annually thereafter [32]. Cervical intraepithelial neoplasia (CIN) 
was treated according to guidelines of women from the general population. The Danish National 
Board of Health recommended that women from the general population aged 23–49 years 
received cervical cytological testing every three years and women aged 50-65 years every five 
years [33].  
 
The SHADE cohort  
The SHADE cohort is an ongoing, multicentre, prospective, observational cohort study of WLWH in 
Denmark attending regular outpatient care for HIV infection. Briefly, study participants were 
enrolled during outpatient visits from 1 February 2011-1 February 2012. Inclusion criteria were 
known HIV-1 infection and ≥18 years of age. Exclusion criteria were pregnancy, prior hysterectomy 
(due to CC or other reasons), and/or alcohol or drug abuse impeding adherence to protocol. 
Previous and current lesions related to HPV infection, such as condyloma acuminata, and prior 
treatment for this, were not an exclusion criterion. A full description of the cohort has previously 
been published [34]. 
 
Interview survey 
Written informed consent was obtained at study entry and a standardized interview among others 
regarding smoking, age at sexual debut, lifetime sexual partners, and contraceptive use was 
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performed (Supplementary file 1). Double manual data entry of the questionnaires was performed 
using the EpiData Entry program [35].  
 
Registries 
Civil Registration System (CRS) 
The CRS is a national registry of all Danish residents [36]. A unique personal identification number 
(PIN) is assigned to each individual. This PIN was used to link to the Danish HIV Cohort Study 
(DHCS). 
 
Danish HIV Cohort Study (DHCS)  
HIV demographics were retrieved from the DHCS, which is a prospective, observational, 
nationwide, multicentre, population-based cohort study of all PLWH seen at the Danish HIV clinics 
since 1 January 1995 [31].  
 
Sample collection & HPV DNA testing 
A trained doctor collected cervical, oral and anal HPV samples using flocked swabs (UTM-RT viral 
transport media Flocked Polyester Swabs, Copan Diagnostics, Inc., Murrieta, CA). Cervical samples 
were collected by inserting a cytobrush through a speculum and rotating it in the cervical canal. 
Oral samples were collected from the tonsils and posterior pharynx by means of firm strokes of a 
cytobrush on both sides. Finally, a cytobrush was inserted into the anal canal and rotated while 
applying gentle pressure to the walls of the canal to collect anal epithelial cells. Samples were 
stored at room temperature and transported to the Department of Pathology, Copenhagen 
University Hospital, Hvidovre. Samples were analysed for HPV using the  CLART HPV2 assay 
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(Genomica, Madrid, Spain) detecting 35 HPV genotypes; 13 hrHPV (hrHPV16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, and 68) and 22 non-oncogenic/low-risk (lr) HPV (lrHPV6, 11, 26, 40, 42, 43, 
44, 53, 54, 61, 62, 66, 70, 71, 72, 73, 81, 82, 83, 84, 85, and 89) [37]. Samples returning invalid 
outcomes were retested. The second result was considered definitive [37].  
Statistical analysis  
Categorical variables were reported as counts and percentages and compared for prevalence and 
concordance using McNemars test and chi-square test or Fisher’s exact test, respectively. 
Continuous variables were summarized as median and interquartile ranges (IQR) or mean and 
ranges and compared using the Wilcoxon rank sum test or Kendall’s Tau-b test. 
 
Univariate and multiple logistic regression analyses were used to identify predictors of overall oral 
and anal HPV/hrHPV presented as odds ratios (OR) and 95% confidence intervals (CI). Due to few 
patients being oral hrHPV positive only four predictor variables were predefined to assess 
predictors of oral HPV infection (Supplementary file 2). Nine candidate predictor variables were 
chosen a priori to study predictors of anal HPV based on knowledge on risk factors of cervical HPV 
[2,38-40] (Table 4). Since duration of ART, prior AIDS and CD4 count are dependent covariates, 
two models were computed for both of the above-mentioned analyses: First, a model where all 
variables except CD4 at inclusion were included and secondly, a model where duration of ART and 
prior AIDS were replaced by CD4. We only present the OR of the CD4 count from the second 
model [18]. The CD4 and HIV RNA values used in this study were the latest values measured 
before inclusion in the study. For variables with more than two outcome categories (df>1), we 
controlled for repeated testing by estimating the combined p-value. Individuals with missing 
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explanatory values were excluded from the multiple regression analyses. The validity of the model 
was tested using the Hosmer and Lemeshow Goodness-of-Fit Test. SAS statistical software version 
9.3 (SAS Institute Inc., Cary, NC, USA) was used for data analysis. HPV genotype distribution figures 
were performed in “R” 3.2.0 [41]. P-values <0.05 were considered statistically significant. 
 
Results 
Characteristics of the cohort 
A total of 334 WLWH consented for study participation [22]. Of 326 cervical, 327 oral and 327 anal 
samples; 295 (90.5%), 273 (83.5%) and 270 (82.6%) yielded sufficient DNA for HPV assessment, 
leaving 214 (64.1%) participants with conclusive HPV test results from all three anatomical sites. 
Baseline characteristics of the 214 included WLWH are presented in Table 1. Median age at 
inclusion was 42.9 years (IQR 36.3-48.4) and median duration of HIV was 11.0 years (IQR 5.3-17.1). 
Overall, 95.3% of the patients were on ART and 80.6% of these had HIV-RNA<40 copies/mL (Table 
1).   
 
Cervical, oral and anal HPV prevalence 
Overall cervical, oral, and anal HPV prevalence was 50.5%, 5.6% and 63.1% (cervical versus oral; 
p<0.0001, cervical versus anal; p<0.0021) (Table 2), hrHPV prevalence was 28.0%, 3.7% and 39.3% 
(cervical versus oral; p<0.0001; cervical versus anal; p=0.0013). Multiple cervical HPV infections 
were more frequent than oral (mean 1.1, range 0-9 vs. mean 0.1, range 0-6), but less frequent 
than anal co-infections (mean 1.5, range 0-14) (Table 2). 
 
Cervical, oral, and anal concordance 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
10 
 
We found no concordance between cervical and oral HPV findings, but anal HPV prevalence was 
positively correlated with cervical HPV infection (Table 2). 
 
Cervical, oral, and anal genotype distribution 
Most frequent cervical hrHPV genotypes observed were hrHPV58 (n=18, 8.4%), 52 (n=11, 5.1%), 
16 (n=11, 5.1%) and 51 (n=11, 5.1%) (Figure 1, Table 3). HrHPV 52 (n=3, 1.4%) was the most 
frequent oral hrHPV infection. Other orally observed hrHPV infections were only present once 
(Figure 1, Table 3). Most frequent anal hrHPV genotypes were hrHPV51 (n=20, 9.3%), 58 (n=19, 
8.9%), 16 (n=15, 7.0%) and 18 (n=15, 7.0%) (Figure 1, Table 3). Table 2 summarizes to which extent 
the observed genotypes were covered by the 2-or 4-valent HPV vaccine. Cervical, oral, and anal 
lrHPV genotype distribution is presented in Figure 1 and Table 3. 
 
Predictors of oral and anal HPV 
We found no predictors of overall oral HPV infection (Supplementary file 2). Overall anal HPV 
infection was associated with cervical HPV infection (adjusted OR per year 4.47 (95%CI 2.25-8.89)) 
(Table 4). In adjusted analyses, we found no predictors of anal hrHPV (data not shown). 
 
Discussion 
In this multicentre, cross-sectional cohort study of WLWH in Denmark, more than half of WLWH 
were concurrently cervical and anal HPV positive, and a large proportion presented with multiple 
anogenital HPV infections. A correlation between cervical and anal hr- and lrHPV was observed 
and cervical HPV infection predicted anal HPV infection. Non-16/18 hrHPV genotypes were 
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predominant at all anatomical sites. Almost half the present hrHPV genotypes would have been 
covered by the 9-valent HPV vaccine. 
 
Cervical HPV prevalence 
Cervical HPV prevalence was 50.5% overall with a hrHPV prevalence of 28.0%, which is 
substantially higher than found amongst women participating in the Danish cervical screening 
program (hrHPV prevalence between 9.4-16.2% dependent on the assay used) [42].  
 
Oral HPV prevalence 
Little is known about the natural history of oral HPV infections [14,43]. However, subclinical 
persistent oral HPV infection is likely to precede OPC [43]. We found an overall oral HPV 
prevalence of 5.6% (hrHPV prevalence: 3.7%), which is somewhat lower than that found in similar 
studies of PLWH where HPV and hrHPV prevalence has been reported at 20-45% and 12-26%, 
respectively [14]. In comparison, a recent review of the HIV-negative population found the overall 
oral HPV prevalence to be an average of 7.5% (range 2.5-20%) [43]. In general, less oral HPV have 
been reported in women, which may reflect reduced HPV seroconversion rates among men versus 
women following genital HPV infection, resulting in greater protection against subsequent oral 
HPV infections in women [13].  
 
Anal HPV prevalence  
Anal HPV and hrHPV prevalence was 63.1% and 39.3%. The higher prevalence in WLWH of anal 
compared with cervical hrHPV, is similar to other reports [23,44]. Moreover, anal hrHPV 
prevalence is higher in WLWH compared with HIV-negative women [45,46]. In WLWH, studies 
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have found an overall anal HPV and hrHPV prevalence of 75.3- 83.15% [44,45] and 47.6-65.0%, 
respectively [23,44,45].  Moreover, a third of WLWH presented with multiple anal HPV infections, 
which is finding consistent with previous research [21,23]. The clinical impact of multiple HPV 
infections is still debatable and the causal attribution of specific genotypes in multiple infections is 
difficult to assess. One study found that multiple hrHPV infections could identify women with 
persistent cervical low-grade squamous intraepithelial lesion and CIN grade 1 [47]. The effect of 
multiple infections on anal intraepithelial neoplasia (AIN) is not well described, though a recent 
meta-analysis notes that single infections with hrHPV16 caused over 85% of AC cases amongst 
HIV-negative, while in PLWH only about 70% of HPV-positive cases harboured hrHPV16 and a third 
of these had multiple infections [16]. In comparison, studies on men who have sex with men 
(MSM) infected with HIV, have found an even higher overall anal HPV prevalence ranging from 86-
100% [48-50] and detection of hrHPV in 85-94% [48,49]. 
 
Cervical, oral, and anal concordance 
We found no genotype concordance between oral and anal HPV, which is consistent with previous 
studies [51,52]. The lack of concordance is suggested to be caused by independent infection 
events, different predilection of the two anatomical sites to various HPV types and/or different 
modes of clearance [14,52]. However, anal overall, hr- and lrHPV prevalence, number of 
genotypes, having all genotypes present targeted by the 9-valent HPV vaccine and presence of ≥1 
genotypes targeted in the 2-, 4-and 9-valent HPV vaccines were positively correlated with being 
cervical HPV positive. The association between concurrent anal and cervical HPV infection 
supports previous reports [21,45,46].  
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HPV genotype distribution  
Cervical hrHPV distribution has previously been published for the entire cohort [18], most 
frequent cervical hrHPV genotypes were hrHPV58, 52, 16 and 51. Though numbers were small, 
hrHPV52 was the most frequent oral HPV infection. HrHPV16, which was found orally in only one 
patient (0.5%), is otherwise the most commonly detected oral hrHPV genotype in PLWH with a 
reported prevalence around 2–6% and involved in 90-95% of HPV-related OPCs [14]. As in the 
present study, where predominant anal hrHPV genotypes were hrHPV51, 58, 16 and 18, Kost et al. 
[45] and de Pokomandy et al. [44] found the most prevalent anal hrHPV genotypes in WLWH to be 
hrHPV51, 16, 31 and 18  and hrHPV16 and 51,  respectively. Whereas hrHPV16 and to some 
extend hrHPV18 are the predominant strains amongst women <35 years of age, other hrHPV 
genotypes becomes more prevalent amongst the >35 years old women [53]. Adding to this, we 
and others have previously reported that differences in genotype distribution between WLWH and 
women from the general population can to some extend be affected by African migrants 
presumably infected with HPV strains predominating in Africa before migrating to Europe [22,54]. 
 
Predictors of oral and anal HPV 
We were unable to study predictors of oral HPV due to few prevalent cases. Previously, oral HPV 
has been associated with HIV infection, smoking, recent tooth-brushing, and more lifetime 
tongue-kissing, and/or oral sex partners [55]. Like others [21,23,45,46], we found an increased risk 
of overall anal HPV infection in WLWH with cervical HPV infection. Previously, prevalent anal 
hrHPV infection have been associated with CD4 count <350/μL and concurrent cervical lesions 
[23]. Predictors of cervical hrHPV infection in the present cohort have previously been reported 
[18].  
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Strengths and limitations 
Strengths include the well-characterized cohort and the use of nationwide registries. Furthermore, 
HPV analyses were performed routinely in a high throughput, quality controlled and quality 
assured clinical laboratory using a well-characterized HPV assay. Limitations include the rather 
high number of inadequate samples. One study found that oral rinse samples were significantly 
more sensitive than self-collected swabs in order to obtain analytically sufficient oral samples [55]. 
However, the use of cytobrushes, as done in the present study, allows for retrieval of cells from 
specified anatomical locations in the oral cavity [24]. Moreover, as persistence of HPV infection is 
required for development of intraepithelial neoplasia, more than a single positive sampling should 
be obtained with a defined time interval between to establish whether the infection is indeed 
persistent rather than transient. Finally, though prophylactic HPV vaccines in PLWH appear safe 
and immunogenic [56] the clinical impact of HPV vaccination in this population is still uncertain.  
Implications for guideline development.  
Regarding primary prevention in the form of vaccine, between 6.7-17.9% of hrHPV infections at all 
three anatomical sites would have been covered by childhood/adolescent vaccination using 2-or 
4-valent HPV vaccine (targeting hrHPV16 and 18), and 42.9-50% of observed hrHPV genotype 
infections would be covered by the 9-valent HPV vaccine (targeting hrHPV16, 18, 31, 33, 45, 52 
and 58). These data supports the new EACS guidelines [46] recommending a three-dose regimen 
of preferably the 9-valent HPV vaccine  in WLWH through age 26, which generates hope for 
WLWH in future HPV vaccinated cohorts. European AIDS Clinical Society (EACS) guidelines 
recommend screening for CC every 1-3 years and AC every 1-3 years with digital rectal exam ± anal 
cytology in MSM and persons with HPV-associated dysplasia [57]. The evidence of benefit for AC 
screening is however unknown [57] and no data on the efficacy of any type of AC screening 
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technique exists [45]. Strategies for AC screening and treatment of AIN are currently under 
investigation in randomized controlled studies [58]. Current evidence for OPC screening in 
asymptomatic adults is insufficient [59]. 
 
Conclusion 
Systematically generated evidence of HPV infection in cohorts of PLWH can help shape primary 
and secondary HPV related cancer prevention. Here we present data from a Danish cohort of 
WLWH, demonstrating that more than half had cervical and anal HPV infection with a large 
proportion presenting with multiple, concurrent anogenital HPV infections. Non-16/18 hrHPV 
genotypes were predominant, which renders the 2- and 4-valent HPV vaccines less effective than 
the 9-valent HPV vaccine.  Regarding secondary prevention, evidence of benefit is still insufficient 
regarding OPC and AC screening, but these data support continued focus on CC screening in 
WLWH.  
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Caption: 
 
Figure 1.  
Comparison of the cervical, oral, and anal human papillomavirus genotype distribution in women 
living with HIV in Denmark (n=214). 
 
+ = Statistically significant positive correlation with cervical HPV infection. 
* = Statistically significant difference in prevalence from cervical HPV infection. 
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Table 1.  
Characteristics of women living with HIV (WLWH) in the study cohort 
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Number of individuals 
 
214 
Duration of HIV (years),  
median (IQR) 
 
11.0 (5.3-17.1) 
Follow-up time, total 
(person-years)  
 
2,412 
Age at inclusion (years),  
median (IQR),  
 
42.9 (36.3-48.4) 
Race, n(%)   
  White 
  Asian  
  Black  
  Other 
  (missing) 
 
 
97 (46.0) 
27 (12.8) 
84 (39.8) 
3 (1.4) 
(3) 
Place of HIV transmission, n(%) 
  Denmark 
  Europe + US 
  Africa 
  Asia 
  Other  
 (missing) 
 
75 (38.9) 
19 (9.8) 
78 (40.4) 
21 (10.9) 
0 (0) 
(21) 
 
Mode of transmission, n(%) 
   Heterosexual 
   IDU 
   Other 
   (missing) 
 
 
189 (90.9) 
11 (5.3) 
8 (3.8) 
(6) 
 
CD4 count at inclusion in SHADE (cells/μL), n(%) 
    <200 
     200-350 
     >350   
   (missing) 
 
 
 
9 (4.6) 
32 (16.4) 
154 (79.0) 
(19) 
ART at inclusion), n(%) 
   Yes 
   No 
   (missing) 
 
On ART with  
HIV RNA<40 copies/mL), n(%) 
   Yes 
   No 
   (missing) 
 
HPV vaccination prior to inclusion, n(%) 
   Yes (4-valent HPV vaccine) 
   Yes (2-valent HPV vaccine) 
   Yes (do not know name of vaccine) 
   No 
   (missing) 
 
 
204 (95.3) 
10 (4.7) 
(0) 
 
 
 
154 (80.6) 
37 (19.4) 
(13) 
 
 
3 (1.4) 
0 (0) 
1 (0.5) 
210 (98.1) 
(0) 
 
Age at sexual debut (years), 
mean (range) 
 
Lifetime sexual partners, n(%) 
   <5 
   5-14 
   15-25 
   >25 
   (missing) 
 
 
17.1 (6-37) 
 
 
68 (31.8) 
82 (38.3) 
28 (13.1) 
36 (16.8) 
 (0) 
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IDU = intravenous drug user, SHADE = Study on HIV, cervical Abnormalities and infections in women in Denmark, ART = combined antiretroviral 
therapy, HPV=Human papillomavirus. 
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Table 2    
Prevalence of cervical, oral, and anal human papillomavirus (HPV) in women living with HIV (WLWH) with sufficient DNA for analyses at all three anatomical sites (n=214)  
        
  
Cervical 
 
 
Oral 
 
 
Anal 
 
p-value 
comparing cervical 
and oral HPV 
prevalence 
p-value 
for correlation  
between cervical 
and oral HPV 
infection 
p-value  
comparing 
cervical and anal 
HPV prevalence 
p-value 
for correlation  
between cervical 
and anal HPV 
infection 
        
HPV sample result, n(%) 
   Overall 
   Positive 
   Negative 
 
   High-risk HPV 
   Positive 
   Negative 
 
   Low-risk HPV 
   Positive 
   Negative 
 
Number of genotypes, mean (range) 
 
Multiple (>1) infections, n(%) 
   Yes 
   No 
 
All high-risk HPV  genotypes present targeted by 
the 2-or 4-valent HPV vaccine1,  
n(% of women being high-risk HPV-positive at 
the specific anatomic location) 
   Yes 
   No 
 
All high-risk HPV genotypes present targeted by 
the 9-valent vaccine2, 
n(% of women being high-risk HPV-positive at 
the specific anatomic location) 
   Yes 
   No 
 
Presence of ≥1 high-risk HPV genotypes from the           
2- or 4-valent HPV vaccine,  
n(% of women being high-risk HPV-positive) 
   Positive 
   Negative 
 
 
108 (50.5) 
106 (49.5) 
 
 
60 (28.0) 
154 (72.0) 
 
 
85 (39.7) 
129 (60.3) 
 
1.1 (0-9) 
 
 
58 (27.1) 
156 (72.9) 
 
 
 
 
 
4 (6.7) 
56 (93.3) 
 
 
 
 
 
30 (50.0) 
30 (50.0) 
 
 
 
16 (26.7) 
44 (73.3) 
 
 
12 (5.6) 
202 (94.4) 
 
 
8 (3.7) 
206 (96.3) 
 
 
7 (3.3) 
207 (96.7) 
 
0.1 (0-6) 
 
 
3 (1.4) 
211 (98.6) 
 
 
 
 
 
1 (12.5) 
7 (87.5) 
 
 
 
 
 
4 (50.0%) 
4 (50.0%) 
 
 
 
 
1 (12.5) 
7 (87.5) 
 
 
135 (63.1) 
79 (36.9) 
 
 
84 (39.3) 
130 (60.7) 
 
 
99 (46.3) 
115 (53.7) 
 
1.5 (0-14) 
 
 
73 (34.1) 
141 (65.9) 
 
 
 
 
 
15 (17.9) 
69 (82.1) 
 
 
 
 
 
36 (42.9) 
48 (57.1) 
 
 
 
 
29 (34.5) 
55 (65.5) 
 
 
<0.00011 
 
 
 
<0.00011 
 
 
 
>0.00011 
 
 
<0.00014 
 
 
<0.00011 
 
 
 
 
 
 
-6 
 
 
 
 
 
 
-6 
 
 
 
 
 
-6 
 
 
 
0.132 
 
 
 
0.222 
 
 
 
0.122 
 
 
0.135 
 
 
0.182 
 
 
 
 
 
 
-6 
 
 
 
 
 
 
0.332 
 
 
 
 
 
-6 
 
 
 
0.00211 
 
 
 
0.00131 
 
 
 
0.121 
 
 
0.00034 
 
 
0.0551 
 
 
 
 
 
 
0.161 
 
 
 
 
 
 
0.251 
 
 
 
 
 
0.481 
 
 
 
<0.00013 
 
 
 
<0.00013 
 
 
 
0.00113 
 
 
<0.00015 
 
 
<0.00013 
 
 
 
 
 
 
0.0682 
 
 
 
 
 
 
0.00892 
 
 
 
 
 
0.00042 
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Presence of ≥1 high-risk HPV genotypes from the 
9-valent HPV vaccine,  
n(% of women being high-risk HPV-positive) 
   Positive 
   Negative 
 
 
 
 
44 (73.3) 
16 (26.7) 
 
 
 
 
5 (62.5) 
3 (37.5) 
 
 
 
 
58 (69.1) 
26 (30.9) 
 
 
 
 
-6 
 
 
 
 
 
0.252 
 
 
 
 
 
1.001 
 
 
 
 
<0.00012 
 
      
 
1 McNemar’s test, 2 Fisher’s test,  
3 Chi-square test, 4 Wilcoxon rank sum test,            
5 Kendall’s Tau-b test, 6 Cannot be estimated. 
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Table 3  
Comparison of cervical, oral and, anal HPV genotype distribution (n=214)  
HPV genotype Cervical 
HPV genotype 
distribution 
n(%) 
Oral 
HPV genotype 
distribution 
n(%) 
Anal 
HPV genotype 
distribution 
n(%) 
Comparison of 
cervical and oral HPV 
infection 
p-value 
Comparison of 
cervical and anal HPV 
infection 
p-value 
hrHPV58 18 (8.4) 1 (0.5) 19 (8.9) <0.0001 1.00 
hrHPV52 11 (5.1) 3 (1.4) 10 (4.7) 0.021 1.00 
hrHPV51 11 (5.1) 1 (0.5) 20 (9.3) 0.0020 0.093 
hrHPV16 11 (5.1) 1 (0.5) 15 (7.0) 0.0063 0.45 
hrHPV35 7 (3.3) 1 (0.5) 11 (5.1) 0.070 0.34 
hrHPV33 7 (3.3) 0 (0) 9 (4.2) 0.016 0.69 
hrHPV18 7 (3.3) 0 (0) 15 (7.0) 0.016 0.057 
hrHPV56 6 (2.8) 1 (0.5) 7 (3.3) 0.063 1.00 
hrHPV31 5 (2.3) 1 (0.5) 8 (3.7) 0.13 0.51 
hrHPV39 4 (1.9) 0 (0) 3 (1.4) 0.13 1.00 
hrHPV68 3 (1.4) 0 (0) 6 (2.8) 0.25 0.38 
hrHPV59 2 (0.9) 1 (0.5) 9 (4.2) 1.00 0.0016 
hrHPV45 2 (0.9) 0 (0) 7 (3.3) 0.50 0.13 
lrHPV53 17 (7.9) 4 (1.9) 29 (13.6) 0.0024 0.058 
lrHPV61 15 (7.0) 1 (0.5) 22 (10.3) 0.00012 0.17 
lrHPV81 12 (5.6) 0 (0) 11 (5.1) 0.00049 1.00 
lrHPV70 11 (5.1) 0 (0) 19 (8.9) 0.00098 0.057 
lrHPV66 11 (5.1) 2 (0.9) 13 (6.1) 0.012 0.75 
lrHPV42 10 (4.7) 1 (0.5) 3 (1.4) 0.012 0.039 
lrHPV6 10 (4.7) 1 (0.5) 14 (6.5) 0.012 0.42 
lrHPV72 9 (4.2) 0 (0) 6 (2.8) 0.0039 0.45 
lrHPV62 9 (4.2) 1 (0.5) 12 (5.6) 0.0078 0.58 
lrHPV82 7 (3.3) 0 (0) 10 (4.7) 0.016 0.61 
lrHPV84 5 (2.3) 0 (0) 7 (3.3) 0.063 0.73 
lrHPV83 5 (2.3) 0 (0) 11 (5.1) 0.063 0.11 
lrHPV54 5 (2.3) 0 (0) 3 (1.4) 0.063 0.73 
lrHPV44 3 (1.4) 0 (0) 7 (3.3) 0.25 0.22 
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lrHPV11 3 (1.4) 1 (0.5) 2 (0.9) 0.50 1.00 
lrHPV89 1 (0.5) 0 (0) 0 (0) 1.00 1.00 
lrHPV85 1 (0.5) 0 (0) 3 (1.4) 1.00 0.50 
lrHPV71 1 (0.5) 0 (0) 3 (1.4) 1.00 0.50 
lrHPV40 1 (0.5) 1 (0.5) 3 (1.4) 1.00 0.63 
lrHPV73 0 (0) 0 (0) 0 (0) 1.00 1.00 
lrHPV43 0 (0) 0 (0) 0 (0) 1.00 1.00 
lrHPV26 0 (0) 0 (0) 0 (0) 1.00 1.00 
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Table 4 
Unadjusted and adjusted odds ratios for predictors of overall anal human papillomavirus (HPV) infection (n =214) 
 
Predictors of anal HPV1 
 
HPV-positive 
 group 
(n=135) 
 
HPV-negative  
group 
(n=79) 
 
Unadjusted 
odds ratios 
 
p-value 
 
Adjusted 
odds ratios2 
 
p-value 
Age at 1 February 2011 
(inclusion), n(%)  
   18-29 years 
   30-50 years 
   ≥50 years 
(missing) 
Combined p-value 
 
12 (8.9) 
93 (68.9) 
30 (22.2) 
(0) 
 
2 (2.5) 
63 (79.8) 
14 (17.7) 
(0) 
 
1.00 
0.25 (0.05-1.14) 
0.36 (0.07-1.82) 
 
- 
0.073 
0.21 
 
0.14 
 
1.00 
0.25 (0.05-1.36) 
0.36 (0.06-2.29) 
 
- 
0.11 
0.28 
 
0.21 
Race, n(%) 
  White  
  Asian  
  Black  
(missing) 
Combined p-value 
 
65 (49.6) 
14 (10.7) 
52 (39.7) 
(4) 
 
32 (41.6) 
13 (16.9) 
32 (41.6) 
(2) 
 
1.00 
0.53 (0.22-1.26) 
0.80 (0.43-1.47) 
 
- 
0.15 
0.47 
 
0.35 
 
1.00 
0.66 (0.24-1.84) 
1.12 (0.49-2.55) 
 
- 
0.43 
0.80 
 
0.59 
Sexual debut, n(%) 
  < 16 years of age 
  ≥ 16 years of age 
  (missing) 
 
47 (34.8) 
88 (65.2) 
 
21 (26.6) 
58 (73.4) 
 
1.00 
0.68 (0.37-1.25) 
 
- 
0.21 
 
1.00 
0.77 (0.35-1.69) 
 
- 
0.51 
ART duration, (years) 
   Median (IQR) 
   (missing) 
 
7.57 (2.59-
12.02) 
 
7.54 (3.93-
10.64) 
 
0.98 (0.93-1.04) 
 
0.56 
 
1.03 (0.95-1.11) 
 
0.52 
AIDS prior to inclusion, n(%) 
   Yes 
   No 
   (missing) 
 
20 (14.9) 
114 (85.1) 
(1) 
 
15 (19.2) 
63 (80.8) 
(1) 
 
1.00 
1.37 (0.65-2.84) 
 
- 
0.42 
 
1.00 
2.18 (0.92-5.15) 
 
- 
0.076 
Smoking status, n(%) 
   Never smoker 
   Current smoker/ Ex-smoker 
 (missing) 
 
70 (51.9) 
65 (48.1) 
 (0) 
 
53 (67.1) 
26 (32.9) 
(0) 
 
1.00 
1.89 (1.06-3.37) 
 
- 
0.031 
 
1.00 
1.91 (0.87-4.19) 
 
- 
0.11 
Number of lifetime sexual 
partners at inclusion, n(%) 
   <5 
   ≥5 
   (missing) 
 
39 (28.9) 
96 (71.1) 
(0) 
 
29 (36.7) 
50 (63.3) 
(0) 
 
1.00 
1.43 (0.79-2.58) 
 
- 
0.22 
 
1.00 
0.92 (0.44-1.93) 
 
- 
0.85 
Use of hormonal contraceptives, 
n(%) 
   Yes  
   No 
(missing) 
 
7 (5.2) 
128 (94.8) 
(0) 
 
8 (10.1) 
71 (89.9) 
(0) 
 
1.00 
2.06 (0.72-5.92) 
 
- 
0.18 
 
1.00 
2.03 (0.53-7.83) 
 
- 
0.31 
Cervical HPV infection, n(%) 
   No 
   Yes  
   (missing) 
 
52 (38.5) 
83 (61.5) 
 
54 (68.3) 
25 (31.7) 
 
1.00 
3.45 (1.92-6.20) 
 
- 
<0.000
1 
 
1.00 
4.47 (2.25-8.89) 
 
- 
<0.0001 
CD4 count at inclusion in SHADE 
(cells/μL),  
    <200 
    200-350 
    >350   
    (missing) 
    Combined p-value 
 
4 (3.3) 
24 (20.2) 
91 (76.5) 
(16) 
 
5 (6.6) 
8 (10.5) 
63 (82.9) 
(3) 
 
1.00 
3.75 (0.81-17.48) 
1.81 (0.47-6.99) 
 
- 
0.092 
0.39 
 
0.15 
 
1.00 
4.14 (0.72-23.74) 
2.13 (0.46-9.91) 
 
- 
0.11 
0.34 
 
0.21 
ART = combined antiretroviral therapy, SHADE = Study on HIV, cervical Abnormalities and infections in women in Denmark. 
1Two models are shown in the table: Age, race, sexual debut, smoking status, number of lifetime sexual partners and use of hormonal 
contraceptives were included in both models, whereas ART duration and AIDS prior to inclusion were included in the first model and replaced by 
CD4 at inclusion in the second model.  We only presented the ORs of the CD4 count from the second model; 2 The validity of the model was 
tested using the Hosmer and Lemeshow Goodness-of-Fit Test. 
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